RTW INVESTMENTS, LP
Q4 2021 13F-HR Holdings
Net value change ($000)
+217,384
(3.3%)
New positions
17
Sold out positions
13
Turnover %
11.2%
Sector allocation + QoQ delta (equities-only)
Holdings aggregated across other managers listed in the original SEC filing. View detailed breakdown
Snapshot: Change Analysis
Compared to Q3 2021
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| RARE | 115,479 | NEW |
| APLS | 94,106 | NEW |
| PEN | 75,735 | 73.8% |
| ARGX | 68,793 | 162.3% |
| PTGX | 57,839 | 186.1% |
| BCYC | 52,913 | NEW |
| TMO | 52,910 | 22.3% |
| ACET | 52,885 | NEW |
| SRPT | 52,433 | NEW |
| Prometheus Biosciences, Inc. | 51,670 | 66.8% |
Top Reduces (Value $000, Stocks/ETFs)
| Dicerna Pharmaceuticals Inc | -152,861 | -100.0% |
| RCKT | -124,626 | -26.5% |
| CLDX | -59,514 | -28.2% |
| DermTech, Inc. | -50,865 | -50.8% |
| VCEL | -42,916 | -19.5% |
| Landos Biopharma, Inc. | -41,903 | -67.1% |
| FULC | -40,353 | -37.1% |
| Mirati Therapeutics, Inc. | -34,988 | -13.3% |
| GH | -34,327 | -29.7% |
| NTRA | -33,613 | -16.2% |
Instrument mix + QoQ Δ (ex-options)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|